Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...

University of Minnesota president Rebecca Cunningham is drawing on her experience as an emergency physician in this ...

CASP, the protein structure prediction contest that launched DeepMind’s Alphafold to international fame and a Nobel Prize, ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

The number of basic science papers published by NIH grant recipients has been falling since 2013, when the agency’s budget ...

The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

You know you’re going to die, right?” When Joy Lisi Rankin’s mother decided not to treat her breast cancer, doctors were ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Omega Funds, the biotech VC firm founded by brash investor Otello Stampacchia, has raised nearly $650 million to invest in ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...